Literature DB >> 28416205

The link between schizophrenia and substance use disorder: A unifying hypothesis.

Jibran Y Khokhar1, Lucas L Dwiel1, Angela M Henricks1, Wilder T Doucette1, Alan I Green2.   

Abstract

Substance use disorders occur commonly in patients with schizophrenia and dramatically worsen their overall clinical course. While the exact mechanisms contributing to substance use in schizophrenia are not known, a number of theories have been put forward to explain the basis of the co-occurrence of these disorders. We propose here a unifying hypothesis that combines recent evidence from epidemiological and genetic association studies with brain imaging and pre-clinical studies to provide an updated formulation regarding the basis of substance use in patients with schizophrenia. We suggest that the genetic determinants of risk for schizophrenia (especially within neural systems that contribute to the risk for both psychosis and addiction) make patients vulnerable to substance use. Since this vulnerability may arise prior to the appearance of psychotic symptoms, an increased use of substances in adolescence may both enhance the risk for developing a later substance use disorder, and also serve as an additional risk factor for the appearance of psychotic symptoms. Future studies that assess brain circuitry in a prospective longitudinal manner during adolescence prior to the appearance of psychotic symptoms could shed further light on the mechanistic underpinnings of these co-occurring disorders while identifying potential points of intervention for these difficult-to-treat co-occurring disorders.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Addiction; Adolescent; Primary addiction; Psychosis; Self-medication

Mesh:

Year:  2017        PMID: 28416205      PMCID: PMC6094954          DOI: 10.1016/j.schres.2017.04.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  143 in total

Review 1.  The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia.

Authors:  Hans O Kalkman
Journal:  Pharmacol Ther       Date:  2006-01-23       Impact factor: 12.310

Review 2.  COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation.

Authors:  Elisa Ira; Martina Zanoni; Mirella Ruggeri; Paola Dazzan; Sarah Tosato
Journal:  J Psychiatry Neurosci       Date:  2013-11       Impact factor: 6.186

3.  Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input.

Authors:  P O'Donnell; A A Grace
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

4.  Brain circuits that link schizophrenia to high risk of cigarette smoking.

Authors:  Lauren V Moran; Hemalatha Sampath; Peter Kochunov; L Elliot Hong
Journal:  Schizophr Bull       Date:  2012-12-12       Impact factor: 9.306

5.  Genome-wide meta-analyses identify multiple loci associated with smoking behavior.

Authors: 
Journal:  Nat Genet       Date:  2010-04-25       Impact factor: 38.330

Review 6.  The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia.

Authors:  Kuei Y Tseng; R Andrew Chambers; Barbara K Lipska
Journal:  Behav Brain Res       Date:  2008-12-03       Impact factor: 3.332

7.  Accentuated behavioral sensitization to nicotine in the neonatal ventral hippocampal lesion model of schizophrenia.

Authors:  Sarah A Berg; R Andrew Chambers
Journal:  Neuropharmacology       Date:  2008-03-28       Impact factor: 5.250

8.  Enhanced methamphetamine self-administration in a neurodevelopmental rat model of schizophrenia.

Authors:  Anne Marie Brady; Sarah E McCallum; Stanley D Glick; Patricio O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2008-05-26       Impact factor: 4.530

9.  Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions.

Authors:  Sharaf S Khan; Roberto Secades-Villa; Mayumi Okuda; Shuai Wang; Gabriela Pérez-Fuentes; Bradley T Kerridge; Carlos Blanco
Journal:  Drug Alcohol Depend       Date:  2012-11-22       Impact factor: 4.492

Review 10.  Association Between Cannabis and Psychosis: Epidemiologic Evidence.

Authors:  Suzanne H Gage; Matthew Hickman; Stanley Zammit
Journal:  Biol Psychiatry       Date:  2015-08-12       Impact factor: 13.382

View more
  33 in total

1.  Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia.

Authors:  Alexis E Whitton; Alan I Green; Diego A Pizzagalli; Robert M Roth; Jill M Williams; Mary F Brunette
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

2.  Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities.

Authors:  Pramod C Nair; Justin M Chalker; Ross A McKinnon; Christopher J Langmead; Karen J Gregory; Tarun Bastiampillai
Journal:  ACS Pharmacol Transl Sci       Date:  2022-02-18

Review 3.  New-Onset Psychotic Symptoms Following Abrupt Buprenorphine/Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report.

Authors:  Yezhe Lin; Alexander D Zhang; Ching-Fang Sun; Justin B White; Ansi Qi; Jessica A Farrell; Robert L Trestman; Rachel K Martin; Anita S Kablinger
Journal:  Psychopharmacol Bull       Date:  2022-06-27

4.  Substance Use in Relation to Mental Illness: A Study of Mexican-Origin Latinos with Schizophrenia and Their Family Members.

Authors:  Mercedes Hernandez; Concepcion Barrio; Paula Helu-Brown; Caroline Lim; Lizbeth Gaona
Journal:  Health Soc Work       Date:  2022-07-13

5.  The Risk of Sexually Transmitted Infections Following First-Episode Schizophrenia Among Adolescents and Young Adults: A Cohort Study of 220 545 Subjects.

Authors:  Chih-Sung Liang; Ya-Mei Bai; Ju-Wei Hsu; Kai-Lin Huang; Nai-Ying Ko; Hsuan-Te Chu; Ta-Chuan Yeh; Shih-Jen Tsai; Tzeng-Ji Chen; Mu-Hong Chen
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

Review 6.  Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability.

Authors:  Balázs Pál
Journal:  Cell Mol Life Sci       Date:  2018-05-15       Impact factor: 9.261

7.  EXTENDED ATTENUATION OF CORTICOSTRIATAL POWER AND COHERENCE AFTER ACUTE EXPOSURE TO VAPOURIZED Δ9 TETRAHYDROCANNABINOL IN RATS.

Authors:  Tapia Foute Nelong; Bryan W Jenkins; Melissa L Perreault; Jibran Y Khokhar
Journal:  Can J Addict       Date:  2019-09

8.  Discontinuity of psychiatric care for patients with schizophrenia, relation to previous psychiatric care and practice variation between providers: a retrospective longitudinal cohort study.

Authors:  Arnold P M van der Lee; Adriaan Hoogendoorn; Lieuwe de Haan; Aartjan T F Beekman
Journal:  BMC Psychiatry       Date:  2021-06-29       Impact factor: 3.630

9.  Psychosocial interventions for people with both severe mental illness and substance misuse.

Authors:  Glenn E Hunt; Nandi Siegfried; Kirsten Morley; Carrie Brooke-Sumner; Michelle Cleary
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12

Review 10.  Binding of clozapine to the GABAB receptor: clinical and structural insights.

Authors:  Pramod C Nair; Ross A McKinnon; John O Miners; Tarun Bastiampillai
Journal:  Mol Psychiatry       Date:  2020-03-13       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.